Dear Partner:

As time flies, we approach the end of 2022; let’s hand in hand celebrate the start of a new year. At this moment, please allow me, on behalf of all employees of Altruist Biologics, to express my most sincere New Year wishes to all partners.

2022 was an unforgettable year and also the year when Altruist Biotech was founded.

In the rapidly changing industry environment, Innovent Biologics group officially launched the brand of Altruist Biotech, a CDMO consisting of her spin-off CMC team. Just like the company's name, we hope to share our technology, experience, and "know-how" with more biotech and biopharma companies, just like the Sherpa people at the foot of Mount Everest, helping climbers "reach the top." We are committed to the important mission of "helping high-quality customers develop high-quality biological drugs that can be used by ordinary people all over the world," hoping to be a bright light to illuminate people's healthy life and benefit more patients.

Upon our establishment, we have the second-largest domestic production capacity and the most commercial production experiences in China. We have more than 1000 professional CMC development and commercial production personnel. The core team has more than 20 years of experience in process and analysis method development, commercial production, and registration and has completed IND and BLA filings of many drugs at home and abroad. We have helped customers bring 8 drugs into the market, have commercialized 4 MAb drugs, and have completed more than 700 commercial batches, with a production success rate of 100%.

Looking back at 2022, it was a challenging year.

Facing the change of identity from the CMC team of a biopharma company to a CDMO, we will continue to follow the service provider role in drug development and help partners solve any challenges in product development, production, and launch. We promise to take advantage of our expertise, that is, from having been the CMC team of a biopharma company. We know how to develop drugs, have rich commercial production experience, and strive to provide customers with high-quality, personalized, and customized development and production services. We will continue to ask ourselves, "what do customers need?" and follow the service concept of "sharing, helping, helping others succeed and win-win" to serve customers. To support more partners, we have a 60000-liter antibody commercial factory in the Suzhou site, whose production line design, construction, and operation standards comply with GMP requirements from NMPA, FDA, and EMA. We have also built a 170000-liter biological drug industrialization base in Hangzhou that meets international standards and will be GMP-ready by the end of 2023. In addition, also we are actively preparing to build overseas capabilities and are committed to providing high-quality services to the world's valued partners.

Looking back at 2022, with the team’s persistent efforts, in half a year, we have provided services to many high-quality partners and completed the signing of hundreds of millions of orders. Thank you again for your trust in us and for letting us participate in developing drugs to change patients’ quality of life and save lives.

Once again, on behalf of every employee of Altruist Biotech, I would like to express my heartfelt thanks for your trust and wish you and your family a lovely holiday and a Happy New Year!

Sincerely,

Kaisong Zhou

CEO, Altruist Biotech